ArticleHemaSphere2026

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Claudia Bellofiore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.